After a 3-month treatment with resveratrol, patients with systolic HF experienced significant reductions in IL-1, IL-6, NT-proBNP, galectin-3, total cholesterol, and low-density lipoprotein cholesterol levels, along with substantial enhancements in cardiac function and quality of life (169). This evidence concerns the gene IL1B and hydrops fetalis.